BioSpace4h
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial
Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...
BioSpace4h
Lexicon to Advance Non-Opioid Painkiller Despite Mid-Stage Trial Failure
Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...
BioSpace5h
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
BioSpace6h
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
BioSpace6h
First Head-to-Head Study Cements Roche’s Xolair as Food Allergy Leader
Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children ...
BioSpace6h
AstraZeneca, Amgen’s Phase III Win Strengthens Case for Tezspire Expansion
The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...
BioSpace8h
The Chilling Effect: State Actions, Patient Data Vulnerability, and DEI Uncertainty
The Dobbs decision has created a chilling effect on telemedicine appointments and doctors’ willingness to provide services ...
BioSpace15h
The Search for the Next Keytruda: Immuno-Oncology’s Next Play
More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...
BioSpace15h
FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...
BioSpace3d
Lilly Hops On Hot Molecular Glue Train With $1.2B+ Magnet Deal
The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...
BioSpace3d
Vertex Severs Liver Gene Therapies Partnership With Verve
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
BioSpace3d
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
In the five weeks since Donald Trump returned as U.S. president, the FDA, NIH and CDC have been thrown into disarray, with ...